Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine

Joseph A. Bocchini; John S. Bradley; Michael T. Brady; Henry H. Bernstein; Carrie L. Byington; Penelope H. Dennehy; Margaret C. Fisher; Robert W. Frenck; Mary P. Glode; Harry L. Keyserling; David W. Kimberlin; Walter A. Orenstein; Lorry G. Rubin; Beth P. Bell; Robert Bortolussi; Richard D. Clover; Marc A. Fischer; Richard L. Gorman; Lucia Lee; Jennifer S. Read; Benjamin Schwartz; Jeffrey R. Starke; Edgar O. Ledbetter; H. Cody Meissner; Larry K. Pickering; Carol J. Baker; Sarah S. Long; Jennifer Frantz

doi:10.1542/peds.2009-0466

Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine

Joseph A. Bocchini, John S. Bradley, Michael T. Brady, Henry H. Bernstein, Carrie L. Byington, Penelope H. Dennehy, Margaret C. Fisher, Robert W. Frenck, Mary P. Glode, Harry L. Keyserling, David W. Kimberlin, Walter A. Orenstein, Lorry G. Rubin, Beth P. Bell, Robert Bortolussi, Richard D. Clover, Marc A. Fischer, Richard L. Gorman, Lucia Lee, Jennifer S. ReadBenjamin Schwartz, Jeffrey R. Starke, Edgar O. Ledbetter, H. Cody Meissner, Larry K. Pickering, Carol J. Baker, Sarah S. Long, Jennifer Frantz

Academic Institute

Research output: Contribution to journal › Review article › peer-review

99 Scopus citations

Abstract

This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.

Original language	English (US)
Pages (from-to)	1412-1420
Number of pages	9
Journal	Pediatrics
Volume	123
Issue number	5
DOIs	https://doi.org/10.1542/peds.2009-0466
State	Published - May 2009

Keywords

Rotavirus gastroenteritis
Rotavirus vaccine

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1542/peds.2009-0466

Cite this

Bocchini, J. A., Bradley, J. S., Brady, M. T., Bernstein, H. H., Byington, C. L., Dennehy, P. H., Fisher, M. C., Frenck, R. W., Glode, M. P., Keyserling, H. L., Kimberlin, D. W., Orenstein, W. A., Rubin, L. G., Bell, B. P., Bortolussi, R., Clover, R. D., Fischer, M. A., Gorman, R. L., Lee, L., ... Frantz, J. (2009). Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine. Pediatrics, 123(5), 1412-1420. https://doi.org/10.1542/peds.2009-0466

Bocchini, JA, Bradley, JS, Brady, MT, Bernstein, HH, Byington, CL, Dennehy, PH, Fisher, MC, Frenck, RW, Glode, MP, Keyserling, HL, Kimberlin, DW, Orenstein, WA, Rubin, LG, Bell, BP, Bortolussi, R, Clover, RD, Fischer, MA, Gorman, RL, Lee, L, Read, JS, Schwartz, B, Starke, JR, Ledbetter, EO, Meissner, HC, Pickering, LK, Baker, CJ, Long, SS & Frantz, J 2009, 'Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine', Pediatrics, vol. 123, no. 5, pp. 1412-1420. https://doi.org/10.1542/peds.2009-0466

@article{4d085b0c5a1a4ec683d2da6bd0415e52,

title = "Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine",

abstract = "This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.",

keywords = "Rotavirus gastroenteritis, Rotavirus vaccine",

author = "Bocchini, {Joseph A.} and Bradley, {John S.} and Brady, {Michael T.} and Bernstein, {Henry H.} and Byington, {Carrie L.} and Dennehy, {Penelope H.} and Fisher, {Margaret C.} and Frenck, {Robert W.} and Glode, {Mary P.} and Keyserling, {Harry L.} and Kimberlin, {David W.} and Orenstein, {Walter A.} and Rubin, {Lorry G.} and Bell, {Beth P.} and Robert Bortolussi and Clover, {Richard D.} and Fischer, {Marc A.} and Gorman, {Richard L.} and Lucia Lee and Read, {Jennifer S.} and Benjamin Schwartz and Starke, {Jeffrey R.} and Ledbetter, {Edgar O.} and Meissner, {H. Cody} and Pickering, {Larry K.} and Baker, {Carol J.} and Long, {Sarah S.} and Jennifer Frantz",

year = "2009",

month = may,

doi = "10.1542/peds.2009-0466",

language = "English (US)",

volume = "123",

pages = "1412--1420",

journal = "Pediatrics",

issn = "0031-4005",

publisher = "American Academy of Pediatrics",

number = "5",

}

TY - JOUR

T1 - Prevention of rotavirus disease

T2 - Updated guidelines for use of rotavirus vaccine

AU - Bocchini, Joseph A.

AU - Bradley, John S.

AU - Brady, Michael T.

AU - Bernstein, Henry H.

AU - Byington, Carrie L.

AU - Dennehy, Penelope H.

AU - Fisher, Margaret C.

AU - Frenck, Robert W.

AU - Glode, Mary P.

AU - Keyserling, Harry L.

AU - Kimberlin, David W.

AU - Orenstein, Walter A.

AU - Rubin, Lorry G.

AU - Bell, Beth P.

AU - Bortolussi, Robert

AU - Clover, Richard D.

AU - Fischer, Marc A.

AU - Gorman, Richard L.

AU - Lee, Lucia

AU - Read, Jennifer S.

AU - Schwartz, Benjamin

AU - Starke, Jeffrey R.

AU - Ledbetter, Edgar O.

AU - Meissner, H. Cody

AU - Pickering, Larry K.

AU - Baker, Carol J.

AU - Long, Sarah S.

AU - Frantz, Jennifer

PY - 2009/5

Y1 - 2009/5

N2 - This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.

AB - This statement updates and replaces the 2007 American Academy of Pediatrics statement for prevention of rotavirus gastroenteritis. In February 2006, a live oral human-bovine reassortant rotavirus vaccine (RV5 [RotaTeq]) was licensed as a 3-dose series for use in infants in the United States. The American Academy of Pediatrics recommended routine use of RV5 in infants in the United States. In April 2008, a live, oral, human attenuated rotavirus vaccine (RV1 [Rotarix]) was licensed as a 2-dose series for use in infants in the United States. The American Academy of Pediatrics recommends routine immunization of infants in the United States with rotavirus vaccine. The American Academy of Pediatrics does not express a preference for either RV5 or RV1. RV5 is to be administered orally in a 3-dose series with doses administered at 2, 4, and 6 months of age; RV1 is to be administered orally in a 2-dose series with doses administered at 2 and 4 months of age. The first dose of rotavirus vaccine should be administered from 6 weeks through 14 weeks, 6 days of age. The minimum interval between doses of rotavirus vaccine is 4 weeks. All doses should be administered by 8 months, 0 days of age. Recommendations in this statement also address the maximum ages for doses, contraindications, precautions, and special situations for administration of rotavirus vaccine.

KW - Rotavirus gastroenteritis

KW - Rotavirus vaccine

UR - http://www.scopus.com/inward/record.url?scp=66049161341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66049161341&partnerID=8YFLogxK

U2 - 10.1542/peds.2009-0466

DO - 10.1542/peds.2009-0466

M3 - Review article

C2 - 19332437

AN - SCOPUS:66049161341

VL - 123

SP - 1412

EP - 1420

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -

Prevention of rotavirus disease: Updated guidelines for use of rotavirus vaccine

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this